Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Part D Price Inflation Rebates Won’t Mean As Much In Inflationary Times

Executive Summary

Fewer rebate penalties than lawmakers expected may be assessed in the coming year because of the current high rate of general inflation.

You may also be interested in...



Eisai/Biogen’s Leqembi Will Launch Below Aduhelm At $26,500 Per Year

With accelerated approval granted and a supplemental filing for full approval in the FDA's hands, Eisai set a price it says is below the “societal value” its Alzheimer’s drug provides as it prepares to seek Medicare coverage. Labeling notably comes with no black box warning or safety restrictions despite various concerns.

Medicare ASP Reporting: CMS Weighing Guidance, Beefed Up Internal Controls To Ensure Accuracy

US Health and Human Services Department Inspector General issues two reports on manufacturer-reported average sales prices and how their accuracy could be improved. ASPs serve as the basis for Medicare Part B reimbursement and will also be used to guide implementation of price inflation-based rebate penalties for Part B drugs beginning in the first quarter of 2023.

Stock Watch: Will Static Pricing And Rising Inflation Compress Pharmaceutical Margins?

Generic pharmaceutical margins are notoriously thin while pricing is limited by intense competition. What happens to margins when raw material and energy pressures rise?

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel